PMID- 25382003
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20181202
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 60
IP  - 10
DP  - 2014 Oct
TI  - [Bortezomib-based therapy in patients with light chain deposition disease].
PG  - 821-6
AB  - Light chain deposition disease (LCDD) is a rare systemic condition caused by 
      monoclonal proliferation of terminally differentiated B-lymphocytes with 
      production of free light chains and their deposition in kidneys or other organs. 
      The aim of our study is to show the pitfalls of the diagnostics, and to 
      demonstrate the effect of bortezomib-based therapy on a series of 4 patients with 
      LCDD, from the point of hematological and organ therapeutic response. We include 
      that bortezomib based treatment provides rapid and effective hematological 
      response. It is, however, often accompanied by adverse events, especially within 
      intensive treatment schedules. The most serious adverse effects includes 
      peripheral neuropathy, which might be dose or treatment-limiting. Less intensive 
      regimens ("bortezomib weekly") suggest an alternative with expectation of lower 
      incidence of adverse effects. Autologous stem cell transplantation is a 
      recommended and relatively safe approach in convenient candidates. Organ response 
      is significantly delayed after hematological response, and organ damage by light 
      chain deposits might not be fully reversible.
FAU - Minarik, Jiri
AU  - Minarik J
FAU - Tichy, Tomas
AU  - Tichy T
FAU - Pika, Tomas
AU  - Pika T
FAU - Bacovsky, Jaroslav
AU  - Bacovsky J
FAU - Adamova, Dagmar
AU  - Adamova D
FAU - Srovnalik, Karel
AU  - Srovnalik K
FAU - Krejci, Karel
AU  - Krejci K
FAU - Zadrazil, Josef
AU  - Zadrazil J
FAU - Scudla, Vlastimil
AU  - Scudla V
LA  - cze
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Lecba bortezomibem u pacientu s onemocnenim z depozice lehkych retezcu 
      imunoglobulinu.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Boronic Acids)
RN  - 0 (Immunoglobulin Light Chains)
RN  - 0 (Pyrazines)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Boronic Acids/administration & dosage/*therapeutic use
MH  - Bortezomib
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Immunoglobulin Light Chains
MH  - Male
MH  - Middle Aged
MH  - Paraproteinemias/complications/*drug therapy
MH  - Pyrazines/administration & dosage/*therapeutic use
MH  - Treatment Outcome
EDAT- 2014/11/11 06:00
MHDA- 2015/10/27 06:00
CRDT- 2014/11/11 06:00
PHST- 2014/11/11 06:00 [entrez]
PHST- 2014/11/11 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - 50177 [pii]
PST - ppublish
SO  - Vnitr Lek. 2014 Oct;60(10):821-6.